Durvalumab after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) - a German radiation oncology survey

被引：0
|
作者：
Kaesmann, Lukas [1 ]
Eze, Chukwuka [1 ]
Taugner, Julian [1 ]
Roengvoraphoj, Olarn [1 ]
Belka, Claus [1 ]
Manapov, Farkhad [1 ]
机构：
[1] Univ Hosp, Munich, Germany
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P245
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)-a German radiation oncology survey
    Kaesmann, Lukas
    Eze, Chukwuka
    Taugner, Julian
    Roengvoraphoj, Olarn
    Belka, Claus
    Manapov, Farkhad
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 288 - 293
  • [2] Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
    Tomasini, Pascale
    Greillier, Laurent
    Boyer, Arnaud
    Jeanson, Arnaud
    Barlesi, Fabrice
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S1032 - S1036
  • [3] Durvalumab treatment after CRT in inoperable stage III NSCLC - a German radiation oncology survey
    Kaesmann, L.
    Taugner, J.
    Eze, C.
    Roengvoraphoj, O.
    Belka, C.
    Manapov, F.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S532 - S533
  • [4] Prospective evaluation of outcome and toxicity of durvalumab treatment after chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) patients
    Kaesmann, Lukas
    Taugner, Julian
    Eze, Chukwuka
    Roengvoraphoj, Olarn
    Belka, Claus
    Manapov, Farkhad
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [5] Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer
    Edwards, Donna M.
    Sankar, Kamya
    Alseri, Aaren
    Jiang, Ralph
    Schipper, Matthew
    Miller, Sean
    Dess, Kathryn
    Strohbehn, Garth W.
    Moghanaki, Drew
    Ramnath, Nithya
    Green, Michael D.
    Bryant, Alex K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (04): : 963 - 970
  • [6] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    [J]. JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [7] Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer
    Robert MacRae
    Hak Choy
    [J]. Current Oncology Reports, 2003, 5 (4) : 313 - 317
  • [8] Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer
    Huang, Yiqing
    Zhao, Joseph J.
    Soon, Yu Yang
    Wong, Alvin
    Aminkeng, Folefac
    Ang, Yvonne
    Asokumaran, Yugarajah
    Low, Jia Li
    Lee, Matilda
    Choo, Joan R. E.
    Chan, Gloria
    Kee, Adrian
    Tay, Sen Hee
    Goh, Boon Cher
    Soo, Ross A.
    [J]. THORACIC CANCER, 2022, 13 (22) : 3152 - 3161
  • [9] How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?
    Bayman, Neil
    Blackhall, Fiona
    McCloskey, Paula
    Taylor, Paul
    Faivre-Finn, Corinne
    [J]. LUNG CANCER, 2014, 83 (02) : 117 - 125
  • [10] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Kim, Young-Hak
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 989 - 990
12345